Maze Therapeutics Quarterly Income Statement
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maze Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Maze Therapeutics generated $0 in revenue, up 0.0% from the same quarter a year earlier. Maze Therapeutics reported a net loss of $44.7 million, compared with a loss of $33.7 million a year earlier. Diluted earnings per share came in at -$0.76.
Summary generated from market data by MetaCap's automated system. Methodology
Maze Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 20.00M | — | — | 0 | — | 0 | 2.50M | 165.00M | — |
| Revenue growth (YoY) | — | — | — | — | -100.00% | — | — | — | — | — |
| Operating Expenses | 48.03M | 46.55M | 38.06M | 32.97M | 36.47M | 35.40M | 29.73M | 26.73M | 25.45M | 28.01M |
| Research & Development | 34.94M | 34.15M | 27.57M | 25.19M | 28.11M | 27.58M | 22.22M | 19.86M | 19.55M | 21.88M |
| Operating Income | -48.03M | -26.55M | -38.06M | -32.97M | -36.47M | -35.40M | -29.73M | -24.23M | 139.56M | -28.01M |
| Interest Expense | 931.00K | 866.00K | — | — | — | — | — | — | — | — |
| Other Income (Expense) | 3.31M | 2.35M | — | — | 2.79M | 2.62M | — | — | — | — |
| Pretax Income | — | — | -34.57M | -30.09M | -33.68M | -32.79M | -29.85M | -25.03M | 140.78M | -32.49M |
| Income Tax | — | — | 0 | 0 | 0 | — | -275.00K | -279.00K | 1.73M | — |
| Net Income | -44.73M | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M | -29.58M | -24.75M | 139.06M | -32.49M |
| Net Income growth (YoY) | — | — | — | — | -124.22% | — | — | — | — | — |
| EPS (Basic) | -0.76 | -0.45 | -0.47 | -0.66 | -0.77 | -1.15 | 19.66 | -10.25 | 5.92 | -13.91 |
| EPS (Diluted) | -0.76 | -0.45 | -0.47 | -0.66 | -0.77 | -1.15 | 22.19 | -10.25 | 3.22 | -13.91 |
| Shares Outstanding (Basic) | 59.00M | 53.90M | — | 45.78M | 43.80M | 28.63M | — | 2.42M | 2.39M | 2.34M |
| Shares Outstanding (Diluted) | 59.00M | 53.90M | — | 45.78M | 43.80M | 28.63M | — | 2.42M | 4.31M | 2.34M |
| EBITDA | -47.64M | -26.11M | -37.56M | -32.39M | -35.83M | -34.72M | -29.02M | -23.44M | 140.41M | -27.06M |
| Operating Margin | — | -132.76% | — | — | — | — | — | -969.16% | 84.58% | — |
| Net Margin | — | -121.04% | — | — | — | — | — | -990.08% | 84.28% | — |
This table shows 10 quarterly periods of Maze Therapeutics's income statement, from Q2 2026 back to Q1 2024, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow MAZE's reporting calendar. What is a income statement?